Background and Aims: Ocular extraintestinal manifestations [O-EIMs] Conclusions: Data on O-EIMs in children are scarce. Prevalence of O-EIMs is lower than in adults but may be underestimated because of the possibility of asymptomatic uveitis; however, the long-term significance of this condition is unknown. Children with CD may be at increased risk of O-EIMs. No recommendations on routine ophthalmological examination can be made, but a low threshold for ophthalmological referral should be maintained. Larger studies in paediatric IBD populations are needed.
Introduction
Inflammatory bowel disease [IBD] , including Crohn's disease [CD] , ulcerative colitis [UC] , and IBD-unclassified [IBD-U], are chronic inflammatory disorders mainly affecting the gastrointestinal tract.
They are associated with various extraintestinal manifestations [EIMs] , which affect approximately 10% to 40% of patients the most common EIMs. Uveitis and episcleritis are among the most commonly reported conditions in adult patients, with a prevalence between 2% and 6% in large cohort studies. 3, 5, 6 However, when a wider spectrum of ocular conditions is considered, a higher prevalence has been reported. [6] [7] [8] [9] O-EIMs may be associated with potentially severe outcomes. Uveitis, in particular, is associated with ocular pain, photophobia, and blurred vision, and when untreated may lead to several ocular complications, including keratopathy, cataract, glaucoma, posterior synechiae, cystoid macular oedema, and permanent vision loss. Other rarer, but potentially severe, ocular manifestations in patients with IBD include retinal vasculitis, central retinal artery/vein occlusion, retrobulbar neuritis, keratopathy, and orbital myositis.
Data on O-EIMs prevalence and clinical course in children are scarce and there are no clear recommendations on which ophthalmological investigations and what follow-up should be offered-unlike other paediatric inflammatory disorders, such as juvenile idiopathic arthritis, for which an ophthalmological screening schedule has been developed. 10 We aimed to review published data on the prevalence and clinical course of O-EIMs from observational studies in children with IBD, in order to better define their epidemiology and clinical characteristics, as well as possibly identifying clinical phenotypes that may be associated with a higher risk of ocular involvement.
Methods
We performed a systematic review of O-EIMs in IBD children according to the MOOSE guidelines. 11 We searched PubMed and EMBASE databases for studies published from inception to January 31, 2018, using the following queries: [1] 
Data selection
Two authors [GO, SN] independently reviewed search results and found a consensus on the articles to be included. Articles references were also considered for additional studies. To be analysed, studies had to report original data on O-EIMs in children with IBD. We included observational studies, as well as case reports. Limits related to age [0-18 years] and languages [English] were applied. Abstracts and unpublished studies were not included. If studies contained data from both adult and paediatric IBD patients, data from the two populations had to be clearly discernible. When articles contained potentially relevant data not fully reported, the authors were contacted by email for further information. Only in two cases were contacted authors able to provide the requested information, which were therefore included in our review, whereas the other authors declared their inability to provide complete data.
Meta-analysis
Mantel-Haenszel weighting and random effects models were used. Statistical heterogeneity across studies was measured using the 
Results
We retrieved 1499 and 264 articles from the query one and two, respectively. We excluded 1470 and 247 articles because they did not meet inclusion criteria. Seven articles were found through both queries. Four other articles were found through the reference list of the included articles. Finally, we selected 43 articles for the analysis [ Figure 1 ].
Prevalence of O-EIMs in children
Fifteen studies, including a total of 7467 patients, reported the prevalence of symptomatic ocular complications in children [ Table 1 ]. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Substantial heterogeneity was present among studies. Timing of data collection varied, as some studies included only O-EIMs present at IBD diagnosis whereas others also considered O-EIMs appearing during follow-up. Studies also differed for O-EIMs inclusion criteria, since some authors reported data only for uveitis, whereas others also included other O-EIMs [e.g. episcleritis, papilledoema, corneal infiltrates], and other articles generically reported 'ocular manifestations' without further details. Finally, the methodology of O-EIMs ascertainment was poorly described or not reported in most studies, making comparative evaluation difficult to perform.
Overall prevalence of O-EIMs in IBD at diagnosis ranged from 0.62% [3/ 
17
]. The largest available study [Jose et al. 12 ] reported data about the first EIM in a cohort of 1649 North-American children with IBD. Among 387 children with a first EIM, 7% [27/387] had an O-EIM; 52 and 13 out of 387 children developed also a second and a third one, respectively, yet data on these EIMs were not detailed and, when contacted authors, could not provide further information; however, an overall incidence rate for anterior uveitis of 0.18 per 100 patientyears was reported. This study was also the only one among larger studies to analyse the prevalence of different types of O-EIMs, with uveitis being the most commonly reported condition [17 patients out of 27 with O-EIMs], followed by papilledoema and corneal infiltrates [7 patients-aggregate data].
A trend towards greater prevalence of O-EIMs in children with CD emerged from several studies, yet this difference did not reach statistical significance, possibly because of the limited number of patients included in each study. We performed a meta-analysis to assess the risk of O-EIMs in children according to the different IBD diagnoses. We compared the prevalence of O-EIMs in children with CD vs children with UC and IBD-U; these two latter groups of patients were analysed together because not all the studies differentiated between them. Only studies including both categories of patients were included in the meta-analysis, to allow direct betweengroups comparison. Children with CD were found to be at increased 15 evaluated the association of O-EIMs with intestinal disease localisation, presence of perianal disease, and patient's age and sex, but no significant association was found. One study ] reported a remarkably high prevalence of uveitis during follow-up in children with UC [four of 113 patients, 3.54%]. However, this study was relatively small and was performed only in patients with UC. Greuter et al. 17 also included data on timing of uveitis appearance in their population: six of 329 patients in their cohort had a diagnosis of uveitis, which occurred at a median time of approximately 7 years after IBD diagnosis, with one case preceding intestinal disease onset. 17 The same study group published also a separate sub-analysis of patients from the same database [the Swiss IBD Cohort Study] evaluated at 10 years [range 108-132 months] of follow-up. 26 After 10 years, age at IBD diagnosis did not appear to influence risk of uveitis, with similar incidence rates in patients with IBD diagnosis <10 years of age, <17 years of age, <40 years of age, and >40 years of age.
No study did provide information about the prevalence of O-EIMs according to the patients' ethnicity. Jose et al. included data on patients' ethnicity, reporting no difference on the overall risk of EIMs, but no information was available for O-EIMs. 12 Finally, few studies provided details about concurrent treatments: Dotson et al. 15 observed a protective effect of treatment with mesalamine/ sulphasalazine, infliximab, and immunomodulators on the overall risk EIMs for patients with moderate to severe disease as compared with patients who had not received these treatments; no data, however, were specifically available for O-EIMs. 15 Finally, Greuter et al. 17 reported the effect of treatment with anti-tumour necrosis factor [TNF] on uveitis: two patients out of three experienced uveitis improvement with treatment; however, in two patients uveitis appeared during anti-TNF treatment. 23 reported a lower prevalence [1/94 patients, 1.06%] of uveitis in a sample of paediatric patients with IBD who had undergone ophthalmological screening evaluation. In this study, only one patient was found to have asymptomatic anterior uveitis on screening slit lamp examination; the same patient also had a history of previous bilateral symptomatic [i.e. eye redness and discomfort] anterior uveitis 7 years earlier, at IBD onset. Uveitis had been treated with dexamethasone eye drops and had not recurred for the 7 years. No other patient had a history of O-EIMs diagnoses. Furthermore, no patient had ocular signs of complications from previous, unrecognised uveitis at ophthalmological evaluation. . 27 Intestinal disease activity was not related to ocular inflammation [active intestinal disease in 6/12 patients with uveitis; no data available from Daum et al.] . In all cases of asymptomatic uveitis, no specific treatment was deemed necessary. Data on short-term follow-up [4-12 months] are available only for patients reported by Daum et al. 27 and Naviglio et al. 23 : uveitis resolved in 6/7 patients overall had either cataract or abnormal intra-ocular pressure. Cataract risk was not correlated with the total dose of corticosteroids, duration of treatment, average daily dose, or number of days on higher doses, whereas increased intra-ocular pressure was correlated with average daily dose in the past 30 days. At follow-up visits, performed at 3-18 months after initial evaluation, dose-related changes in ophthalmological findings were observed. Notably, cataract regression was observed in two patients lowering the prednisone daily dose to less than 10 mg/day of prednisone. Similarly, increased ocular pressure responded to lowering of dose to less than 10 mg/day; on the other hand, an increase in corticosteroid dose was associated with abnormal intra-ocular pressure in some patients with previously normal findings.
Screening for O-EIMs in children

Case reports
We retrieved 23 case reports/case series including 24 children with O-EIMs [ 
Discussion
Data on ocular involvement in children with IBD are scarce and fragmented. Substantial heterogeneity among studies and several methodological issues currently limit the complete evaluation of this topic. Among cohort studies reporting prevalence of O-EIMs in children with IBD, inclusion criteria for O-EIMs were, in fact, highly variable, with some authors focusing only on selected conditions [e.g. uveitis] and others reporting the presence of 'ocular manifestations' without further specification. Furthermore, criteria for the diagnosis of O-EIMs are not fully defined in most studies. Notwithstanding these limitations, data from cohort studies indicate a lower prevalence of ocular involvement in children [0.6-1.8%] than in adults [2-6%] . Data on different types of O-EIMs are even scarcer, with only one report [Jose et al. 12 ] showing different prevalence for selected ocular conditions [uveitis, papilledoema, corneal infiltrates]. According to this study, uveitis represents the most common O-EIM in children with IBD. Subtype and localisation of uveitis were not indicated, yet in adult patients anterior uveitis [i.e. iritis/ iridocyclitis] is predominant. 54 Data on prevalence of other O-EIMs, such as episcleritis/scleritis or rarer conditions such as orbital myositis, are not available, and only data from case reports are presented.
O-EIMs can affect both CD and UC patients, yet our meta-analysis showed that children with CD are at increased risk of O-EIMs as compared withchildren with other paediatric IBD, with an odds ratio of 2.70. No significant study heterogeneity was detected yet, given the paucity of information available, we had to consider together in the analysis studies on EIMs at diagnosis and during the follow-up. ; however, data from studies on adult patients are conflicting, with only some studies reporting a significantly increased prevalence of O-EIMs in CD patients, whereas in others the difference appears to be non-significant. 1, 3, 56, 57 Data on timing of O-EIMs in children are also scarce. Greuter et al. 17 reported a median time of 7 years after IBD diagnosis for uveitis onset, although substantial variability was observed. Occurrence of O-EIMs before gastrointestinal symptoms onset is also possible, even though in a minority of patients; O-EIMs that have been reported to precede intestinal disease include uveitis and orbital myositis. Results from the largest study [Jose et al., 2009 12 ] indicate that the prevalence of uveitis increases with time [incidence rate: 0.18 cases per 100 patient-years]. Herzog et al. 26 reported no difference for uveitis rates according to age at IBD diagnosis when patients were evaluated after 10 years, possibly indicating that age at IBD onset does not influence uveitis risk per se.
Very little data are available also for correlation of O-EIMs with intestinal disease activity. Although uveitis is classically considered to be unrelated to intestinal disease activity, some studies on adult patients actually found a significant correlation with disease activity in patients with CD [but not those with UC].
1 Few studies specified concurrent treatments in IBD patients, which may possibly have an effect on the risk of O-EIMs during follow-up. Dotson et al. 15 reported a protective effect of immunomodulators and anti-TNF on the overall risk of EIMs in their cohort, yet no data were available for O-EIMs. Systemic immunomodulatory treatments could possibly reduce the risk of inflammatory O-EIMs, but this relationship may not be straightforward. In fact, Greuter et al. 17 reported a good response of uveitis to anti-TNF antibodies in two out of three patients, yet the same authors detected uveitis during anti-TNF treatment in two other patients.
We did not find evidence of a difference in prevalence of O-EIMs according to patients' ethnicity. No study provided information on patients' ethnicity as related to O-EIMs, yet among prevalence studies several world regions were actually included [North America, Western Europe, Turkey, Saudi Arabia, South Korea] and no difference in overall prevalence was observed. Jose et al. 12 reported no significant association for patients' ethnicity with overall EIMs prevalence, but no specific data were available for O-EIMS. Another study, by Eidelwein et al., compared EIMs prevalence between White and African American children in North America. 58 This study, however, could not be included in the prevalence analysis because it did not show exact figures of the condition, stating only that uveitis prevalence was 'less than 3%' in both groups of patients. Contacted authors also could not provide further information. Nonetheless, no difference in overall EIMs prevalence was reported. Similarly, White et al. found no difference in overall EIMs prevalence in African American children with IBD as compared with other ethnic groups; however, subanalysis of different types of EIMs was not performed, nor could contacted authors provide further information. 59 Remarkably, data from adult patients seem to suggest that prevalence of uveitis may be higher in African American CD patients as compared with other ethnic groups. [60] [61] [62] The recognition of subclinical uveitis by slit lamp examination in screening evaluation in small samples of asymptomatic children with Table 3 .
Continued
IBD raises concerns about under-diagnosis of a potentially invalidating condition. Three studies [Daum et al., 1979 27 ; Hofley et al.
1993;
28 Rychwalski et al. 1997 29 ] showed a significantly increased prevalence of subclinical uveitis [4.1-23 .1%] compared with that reported in cohort populations. It may be worth noting that these studies were performed more than 20 years ago [between 1979 and 1997] , before the introduction of biologic anti-tumour necrosis factor alpha agents and the wider use of immune modulators, which allow better control of both gastrointestinal manifestations and EIMs. 63, 64 The more recent report by Naviglio et al., 23 while confirming the existence of subclinical uveitis in children with IBD, indicated a lower prevalence [1.06%], in line with the prevalence from cohort studies. In all these studies, asymptomatic uveitis was anterior, confirming this as the most common type of uveitis associated with IBD in children, even though other types of uveitis [e.g. intermediate uveitis] are also possible. 47 Asymptomatic uveitis did not seem to correlate with intestinal disease activity. Interestingly, some clinical characteristics recurred among patients with asymptomatic uveitis: they were more commonly adolescent males with CD and with colonic involvement [13/14 patients] . This may confirm that CD patients are at increased risk of O-EIMs. Recent data have suggested that eye-specific autoreactive T cells may be activated in the gut from an antigen-dependent cross-reaction on commensal microbiota. 65 Abnormal gut permeability in CD and increased density of microbiota in the colon could explain the increased risk of O-EIMs in these patients. However, the low number of cases does not allow us to draw a general conclusion nor to identify other significant characteristics.
Clinical implications of asymptomatic uveitis are unclear. In fact, most cases were diagnosed as mild uveitis, and both Daum et al. 27 and Naviglio et al. 23 reported spontaneous resolution of ocular inflammation without specific treatments, suggesting that asymptomatic uveitis in children with IBD may be transient and self-limiting. Remarkably, no studies detected evidence of ocular complications from previous unrecognised uveitis, suggesting that this type of ocular manifestation may not be aggressive nor lead to complications, at least in children with IBD. This is in sharp contrast with asymptomatic uveitis associated with other paediatric chronic inflammatory disorders, such as juvenile idiopathic arthritis-associated uveitis, which has a high potential for ocular complications and visual impairment. 66 Nevertheless, the natural history of asymptomatic uveitis in IBD is poorly known, and therefore definitive conclusions cannot be drawn. Notably, several treatments used in IBD are also effective for uveitis, and thus uveitis may also benefit from systemic treatments used to control intestinal disease. New studies are needed to outline specific phenotype risk and orientate proper follow-up for these patients.
Iatrogenic ocular complications, mainly corticosteroid-induced posterior subcapsular cataract and increase of intra-ocular pressure, should also always be considered in children with IBD receiving corticosteroids. Available data on this complication come mostly from the case-control study by Tripathi et al. 30 The majority of children [52%] developed either cataract or alteration of intra-ocular pressure; however, this study was performed mainly on children receiving long-term corticosteroid treatment, an eventuality that has now become less frequent, as corticosteroids are considered more as a 'bridge therapy'. There are few data in medical literature defining timing and dose-related risk of corticosteroid-induced ocular complications in children. It is now well recognised that there is a high inter-individual variability in sensitivity to ocular adverse effects of corticosteroids, with some patients free of ocular complications after years of corticosteroid treatment, whereas in others they may develop rapidly [even as soon as after 2 weeks of treatment]. 67 Data from adult patients seem to indicate that the overall risk is doseand time-related, even though a 'safe dose' does not seem to exist. 68 Notably, corticosteroid-induced complications, especially increased intra-ocular pressure, did respond to dose lowering to less than 10 mg/day of prednisone in the study by Tripathi et al. , 30 yet we have not enough data to consider this as a 'safe' dose. Therefore, at present, a precise threshold for corticosteroid dose or treatment duration to guide ophthalmological evaluation cannot be clearly defined. In the study by Tripathi et al., 30 the risk of cataract was not correlated to treatment duration or steroid dose, whereas the risk of abnormal intra-ocular pressure was associated to the average dose in the previous 30 days. It may be possible therefore to consider that this is an adequate timing for alterations of intra-ocular pressure to develop. Thus it could be reasonable to suggest that in children in whom systemic corticosteroids are considered for longer periods of time and not as a 'bridge therapy' [i.e. in whom tapering and suspension are not programmed after 1 month] an ophthalmological evaluation, including intra-ocular pressure measurement, should be considered after 1 month of therapy. Timing for subsequent evaluations should be decided by the referral ophthalmologist, as there are no data to guide patient management. It is noteworthy that in the study by Tripathi et al., 30 some patients with a previously normal ophthalmological evaluation developed complications after a significant increase in their daily corticosteroid dose, so this should also be taken in consideration in guiding follow-up. All these recommendations are based on low/moderate quality evidence [one case-control study], and therefore their strength should be considered as weak. Patients on very long-term corticosteroid treatment [i.e. treatment continuing for several months/years], however, are at high risk of ocular complications and a strict ocular follow-up should be offered.
Available case reports of O-EIMs define a wide array of ocular conditions that have been reported in children with IBD. However, for some of them it is currently not possible to determine whether they were simply coincidental, though similar manifestations have been reported in adult patients. Presenting symptoms varied widely, from mild ocular redness or discomfort to complete loss of vision, highlighting the need not to underestimate ocular complaints in these patients. Reported O-EIMs can be roughly classified into inflammatory and vascular conditions. The first group includes uveitis, episcleritis, orbital myositis/ pseudotumour, dacryoadenitis, and optic neuritis. Orbital pseudotumour, which identifies any inflammatory enlargement of intraorbital structural elements, 69 despite being a rare condition, was one of the most commonly reported O-EIMs in case reports. Although the clinical manifestations may vary widely, depending on the structures affected, they often included ocular/orbital pain, diplopia, ophthalmoplegia, proptosis, eyelid swelling, and reduced visual acuity. Almost all cases involving an inflammatory O-EIM resolved with treatment, which usually included systemic corticosteroids.
Among vascular conditions, we identified reports on retinal artery or vein occlusion and choroidal neovascular membrane; these complications may also share an inflammatory pathogenesis, possibly due to retinal vasculitis, which has been associated with IBD in adults. 70 In most cases, vascular conditions resulted in some residual visual impairment despite treatment. Notably, also among case reports there was a preponderance of children with CD [CD/ UC = 18/5], thus possibly confirming a greater incidence of O-EIMs in CD patients.
In conclusion, available data indicate that prevalence of O-EIMs in children is lower than in adult patients, yet children with CD seem to be at increased risk as compared with other groups of patients. Prevalence of O-EIMs in children may be underestimated in consideration of the possibility of asymptomatic uveitis, which has not been described in adults. 71 The significance of this condition, however, is unclear, as all reported cases were mild and self-limiting, with no evidence of ocular complications from underdiagnosis. Nevertheless, data on natural history of this manifestation and long-term followup are lacking. It has been recently suggested that annual screening eye examination should be considered in all children with IBD 72 ; however, this is often not performed in clinical practice, nor it is possible to define the cost-benefit ratio of such an approach. Currently, the paucity of data on O-EIMs in children does not allow us to draw clear conclusions on which ophthalmological follow-up should be provided. An option may be to perform ophthalmological evaluation at IBD diagnosis in order to have a baseline reference, but we cannot provide any evidence for this suggestion. On the other hand, we recommend that a low threshold for ophthalmological referral should be maintained in all children with IBD, both at the diagnosis and during follow-up. Available data, in fact, show that most children with O-EIMs presented some ocular signs or symptoms, and therefore ocular complaints should never be dismissed; both health care providers and patients/care givers should be instructed about the increased risk of ocular complications in children with IBD. Since available data indicate a higher incidence of O-EIMs in children with CD, especially if colonic involvement is present, this subset of patients may be considered at higher risk of O-EIMs in clinical practice, but further studies on larger groups of patients are needed. Finally, patients receiving systemic corticosteroids for more than brief periods may probably benefit from ophthalmological evaluations, including intra-ocular pressure measurement. A strict follow-up should be offered in patients receiving long-term corticosteroid treatment, as these children are at increased risk for iatrogenic ocular complications.
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